4Hickie IB, Rogers NL. Novel melatonin-based therapies: poten- tial advances in the treatment of major depresslon[J]. Lancet, 2011, 378(9791): 621-631.
5Germain A, Kupfer DJ. Circadian rhythm disturbances in depres- sion[J]. Hum Psychopharmacol, 2008, 23(7): 571-585.
6Souetre E, Salvati E, Belugou JL, et al. Circadian rhythms in de- pression and recovery: evidence for blunted amplitude as the main chronobiological abnormality[J]. Psychiatry Res, 1989, 28 (3): 263-278.
7de Bodinat C, Guardiola-Lemaitre B, Moeaer E, et al. Agomela- tine, the first melatonergie antidepressant: discovery, character- ization and development[J]. Nat Rev Drug Discov, 2010, 9(8): 628-642.
8Monteleone P, Maj M. The circadian basis of mood disorders: re- cent developments and treatment implications[J]. Eur Neuropsy- chopharmacol, 2008, 18(10): 701-711.
9Kasper S, Hamon M. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action[J]. World J Biol Psychiatry, 2009, 10(2): 117-126.
10Tardito D, Molteni R, Popoli M, et al. Synergistic mechanisms in- volved in the antidepressant effects of agomelatine[J]. Eur Neuro- psychopharmacol, 2012, 22 (Suppl 3) : $482-486.
